z-logo
open-access-imgOpen Access
Long-term stability of temocillin in elastomeric pumps for outpatient antibiotic therapy in cystic fibrosis patients
Author(s) -
Stéphane Carryn,
N. Couwenbergh,
Paul M. Tulkens
Publication year - 2010
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkq229
Subject(s) - cystic fibrosis , antibiotic therapy , medicine , antibiotics , term (time) , intensive care medicine , microbiology and biotechnology , biology , physics , quantum mechanics
s of the Second ASM Conference on Antimicrobial Resistance in Zoonotic Bacteria and Foodborne Pathogens in Animals, Humans and the Environment, Toronto, 2010. Abstract 87A, p. 13. American Society for Microbiology, Washington, DC, USA. 3 Garcı́a-Fernández A, Fortini D, Veldman K et al. Characterization of plasmids harbouring qnrS1, qnrB2 and qnrB19 genes in Salmonella. J Antimicrob Chemother 2009; 63: 274–81. 4 Hammerl JA, Beutlich J, Hertwig S et al. pSGI15, a small ColE-like qnrB19 plasmid of a Salmonella enterica serovar Typhimurium strain carrying Salmonella genomic island 1 (SGI1). J Antimicrob Chemother 2010; 65: 173–5. 5 Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother 2009; 53: 2227–38. 6 Jones C, Stanley J. Salmonella plasmids of the pre-antibiotic era. J Gen Microbiol 1992; 138: 189–97. 7 Ahmed AM, Motoi Y, Sato M et al. Zoo animals as reservoirs of Gram-negative bacteria harboring integrons and antimicrobial resistance genes. Appl Environ Microbiol 2007; 73: 6686–90. 8 Jones TF, Ingram LA, Cieslak PR et al. Salmonellosis outcomes differ substantially by serotype. J Infect Dis 2008; 198: 109–14. J Antimicrob Chemother 2010 doi:10.1093/jac/dkq229 Advance publication 24 June 2010 Long-term stability of temocillin in elastomeric pumps for outpatient antibiotic therapy in cystic fibrosis patients Stéphane Carryn1,2†, Nathalie Couwenbergh1 and Paul M. Tulkens1* Unité de pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, B-1200 Bruxelles, Belgium; Eumedica S.A., B-7170 Manage, Belgium *Corresponding author. Unité de pharmacologie cellulaire et moléculaire, Université catholique de Louvain, UCL7370 avenue E. Mounier 73, B-1200 Bruxelles, Belgium. Tel: +32-2-7647236; Fax: +32-2-7647373; E-mail: tulkens@facm.ucl.ac.be †Present address: GlaxoSmithKline Biologicals S.A., B-1300 Wavre, Belgium.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom